Phenylketonurias
BioMarin Drops Preclinical PKU Drug Once Seen as Potential Palynziq Successor
BioMarin; PKU; Palynziq; BMN 390; drug development; R&D pipeline; immunogenicity
Otsuka Pharmaceutical Acquires Jnana Therapeutics for $800M to Develop PKU Treatment
Otsuka Pharmaceutical, Jnana Therapeutics, PKU, phenylketonuria, JNT-517, RAPID chemoproteomics platform, rare metabolic disorder, biotech acquisition